Next Phase Newsletter

A firm with offices in Western Europe makes biotech and medtech investments from an evergreen fund. The firm typically makes initial investments of EUR 3-10m at the Series A or B stage, and may commit EUR 25m over the life of an investment. The firm invests across Europe, and aims to make at least 4 life science investments per year (2-3 biotech and 1-2 medtech investments).

The firm invests across the biotech and medtech sectors. Within the biotech sector, the firm prefers to invest in platform technologies rather than in single asset companies, and will invest as early as the preclinical stage. The firm will consider any therapeutic area, and has an interest in orphan drugs; due to having a large existing portfolio in immuno-oncology, the firm is not emphasizing this field at present. The firm prefers opportunities that do not require very large clinical trials. For medical devices, the firm prefers to invest in companies with products with a global potential, that are close to acquiring a CE Mark and that are preparing commercialization. The firm is also interested in enabling technologies such as next-gen PCR and lab equipment.

The firm does not invest in company-creation opportunities: the firm prefers to work with companies that already have high-quality management teams that have proven themselves through past success in the life science industry, and who have a strong network within the industry. The firm also considers the company’s capital efficiency, future capital needs, and the strength of the company’s prior investment syndicate. The firm prefers to lead or co-lead investments, and is a highly activist investor at a portfolio company’s board level.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A family office based in the USA is looking to invest in technologies related to ophthalmology and oncology that are in the pre-clinical to PhI stages, and will generally invest $5-10M in series A rounds. The firm is willing to invest globally, with a special interest in companies based in North America, Europe and China.

The firm is interested in therapeutics, medical device and diagnostics companies with technologies in the ophthalmology and oncology spaces. The firm may consider digital health companies as well. For ophthalmology-related companies, the firm is most interested in small molecules or combination devices. For oncology-related companies, the firm prefers I/O technologies or diagnostics.

The firm prefers to take a board seat after investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Corporate Finance firm focused on venture and private equity investments supports SMEs across Europe with attention to Austria. The company has built a track record of creating significant value as investors by developing deep industry expertise in sectors including renewable energy, high-tech and bio-tech.

The firm is interested in companies in the therapeutics and diagnostics space in particular and is open to considering medical device companies as well. The firm is open to any indication and sub-sector but requires that the firm’s asset be ready to enter a Phase I study in order to be considered.

The firm is looking for private companies with exceptional management teams in place. The firm often looks to take a board seat and provide a lot more than just financial aid to companies they invest in.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based Switzerland raised a new fund in 2019.  The firm generally makes equity investments into internet and health tech companies at seed and early stages. The typical investment size ranges from €0.2 million to € 5 million. The firm plans to make 15-20 investments in the next 3 years and it will invest in companies based in Europe, with a core focus on Switzerland and Germany.

The firm is currently looking for new opportunities in the area of platform technologies, diagnostics, digital health, medtech etc.. The firm focuses on companies developing biotech platforms, research tools and digital health startups. The firm will not invest in pure drug development companies. In the past, the firm was active in companies developing proteomics platform technology, 3D micro tissues technology, diagnostic services, vaccines, antibody development platforms and a technology platform to develop virus envelopes.

The firm typically seeks to invest in private companies with convincing founders or managers. The firm will consider pre-revenue companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment firm based in Austria manages a total of EUR 50 million in capital, and invests in seed and early stage opportunities in Austria. The firm initially invests up to EUR 1 million, with further capital reserved for potential follow-on rounds.

The firm will consider investing in any area of life science technology, including biotech, medical devices, diagnostics, and also agtech and environmental biotech. The firm is open to investing in early-stage companies that have not yet commenced human clinical trials; however, the firm will only invest in companies that have a working prototype or animal data for their product. While the firm will consider any technology or indication area, the firm generally prefers not to invest in health apps, or in fields such as oncology that incur high costs for clinical development.

The firm focuses on investing in their local area close to Vienna. The firm is open to being a lead investor but prefers not to be the sole investor in a round; the firm syndicates with other VCs and other sources of capital.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A newly established Healthcare focused fund with offices in USA, Europe, and China, is broadly focused in Life Sciences with strong preference for early stage opportunities. The senior team members have strong operating experience in biotech and pharma companies, and would like to lead investments and play active roles in their portfolio companies.

The firm is particularly keen on cardiovascular, regenerative medicine, and ophthalmology related opportunities. The firm is otherwise agnostic in regards to specific disease indications and is willing to look at all opportunities within the early stage, however diagnostics is currently considered as a low priority.

As the firm seeks to be an active lead investor, the firm strongly prefers a board seat in companies that they have invested in. Outside of the board requirement, the firm is looking for strong management teams that demonstrate the capability to move their technology forwards.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An international firm conducts global business development and licensing searches in all stages of clinical diagnostics research and development, regardless of the technology involved. The firm employs a variety of deal structures including IP rights in- and out- licensing, product or technology co-development, and M&A.

The firm is interested in new technologies in point of care diagnostics, molecular diagnostics, tissue diagnostics, bioinformatics, and instrumentation, sequencing and associated software. The firm’s indications of interest include oncology, sepsis, pre-natal health and women’s health, bone metabolism, cardiovascular disease, diabetes and metabolic disease, kidney disease, infectious disease, and genetic disorders.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.